UBS AM’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.4K | Hold |
1,700
| – | – | ﹤0.01% | 3127 |
|
|
2026
Q1 | $14.2K | Buy |
1,700
+1,046
| +160% | +$11K | ﹤0.01% | 3220 |
|
|
2025
Q4 | $9.42K | Buy |
+654
| New | +$8.15K | ﹤0.01% | 2865 |
|
|
2025
Q1 | – | Sell |
-72,183
| Closed | -$558K | – | 2690 |
|
|
2024
Q4 | $558K | Buy |
72,183
+6,105
| +9% | +$57.3K | ﹤0.01% | 2540 |
|
|
2024
Q3 | $693K | Sell |
66,078
-4,880
| -7% | -$59.5K | ﹤0.01% | 2540 |
|
|
2024
Q2 | $830K | Buy |
70,958
+32,414
| +84% | +$505K | ﹤0.01% | 2463 |
|
|
2024
Q1 | $812K | Hold |
38,544
| – | – | ﹤0.01% | 2109 |
|
|
2023
Q4 | $692K | Hold |
38,544
| – | – | ﹤0.01% | 2211 |
|
|
2023
Q3 | $634K | Buy |
38,544
+13,237
| +52% | +$240K | ﹤0.01% | 2187 |
|
|
2023
Q2 | $479K | Hold |
25,307
| – | – | ﹤0.01% | 2338 |
|
|
2023
Q1 | $479K | Sell |
25,307
-9,191
| -27% | -$203K | ﹤0.01% | 2338 |
|
|
2022
Q4 | $782K | Sell |
34,498
-1,997
| -5% | -$45.1K | ﹤0.01% | 1978 |
|
|
2022
Q3 | $965K | Hold |
36,495
| – | – | ﹤0.01% | 1988 |
|
|
2022
Q2 | $901K | Sell |
36,495
-1,295
| -3% | -$32.4K | ﹤0.01% | 2023 |
|
|
2022
Q1 | $1.25M | Hold |
37,790
| – | – | ﹤0.01% | 2022 |
|
|
2021
Q4 | $1.24M | Hold |
37,790
| – | – | ﹤0.01% | 2100 |
|
|
2021
Q3 | $1.58M | Sell |
37,790
-1,653
| -4% | -$59.5K | ﹤0.01% | 1936 |
|
|
2021
Q2 | $1.53M | Buy |
39,443
+2,612
| +7% | +$93.4K | ﹤0.01% | 1976 |
|
|
2021
Q1 | $1.26M | Buy |
36,831
+9,941
| +37% | +$424K | ﹤0.01% | 1976 |
|
|
2020
Q4 | $1.22M | Hold |
26,890
| – | – | ﹤0.01% | 1896 |
|
|
2020
Q3 | $740K | Hold |
26,890
| – | – | ﹤0.01% | 1960 |
|
|
2020
Q2 | $990K | Buy |
26,890
+4,525
| +20% | +$169K | ﹤0.01% | 1817 |
|
|
2020
Q1 | $724K | Sell |
22,365
-98,759
| -82% | -$4.11M | ﹤0.01% | 1821 |
|
|
2019
Q4 | $4.96M | Buy |
121,124
+719
| +0.6% | +$28.4K | ﹤0.01% | 1191 |
|
|
2019
Q3 | $4.29M | Buy |
120,405
+691
| +0.6% | +$28K | ﹤0.01% | 1263 |
|
|
2019
Q2 | $6.15M | Buy |
119,714
+752
| +0.6% | +$37.5K | ﹤0.01% | 1127 |
|
|
2019
Q1 | $6.82M | Buy |
118,962
+9,638
| +9% | +$477K | 0.01% | 1039 |
|
|
2018
Q4 | $4.59M | Sell |
109,324
-6,427
| -6% | -$377K | ﹤0.01% | 1122 |
|
|
2018
Q3 | $8.74M | Buy |
115,751
+103,628
| +855% | +$7.47M | 0.01% | 970 |
|
|
2018
Q2 | $870K | Buy |
+12,123
| New | +$579K | ﹤0.01% | 1868 |
|
|
2016
Q1 | – | Sell |
-108,954
| Closed | -$1.81M | – | 2655 |
|
|
2015
Q4 | $1.81M | Sell |
108,954
-9,909
| -8% | -$197K | ﹤0.01% | 1483 |
|
|
2015
Q3 | $2.62M | Buy |
+118,863
| New | +$3.03M | ﹤0.01% | 1301 |
|
Other funds holding RGNX
RG
UBS AM's RGNX Position: Q2 2026 in Review
UBS AM held its Regenxbio (RGNX) position steady in Q2 2026 at 1,700 shares worth $20.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3127.
UBS AM first reported a position in RGNX in Q3 2015 and has held it in 32 quarters since. The position peaked at $8.74M in Q3 2018. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- UBS AM held 1,700 shares of Regenxbio worth $20.4K as of Q2 2026.
- UBS AM left its Regenxbio share count unchanged in Q2 2026.
- Regenxbio made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3127 holding.
- UBS AM first reported a position in Regenxbio in Q3 2015 and has held it in 32 quarters since.
- UBS AM's Regenxbio position peaked at $8.74M in Q3 2018.
- 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.